Last reviewed · How we verify
Intravesical Gemcitabine and Docetaxel
Intravesical Gemcitabine and Docetaxel is a Small molecule drug developed by Michael A. O'Donnell. It is currently in Phase 2 development.
At a glance
| Generic name | Intravesical Gemcitabine and Docetaxel |
|---|---|
| Sponsor | Michael A. O'Donnell |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Intravesical GEM/DOCE for HR BCG-Unresponsive NMIBC (PHASE2)
- A Study of Adjuvant NDV-01 (Sustained-release Gemcitabine-docetaxel) for the Treatment of Intermediate Risk NMIBC Following TURBT (PHASE3)
- Intravesical Gemcitabine and Docetaxel for Low Grade Intermediate Risk Bladder Cancer (PHASE2)
- A Trial to Evaluate Intravesical Nadofaragene Firadenovec Alone or in Combination With Chemotherapy or Immunotherapy in Participants With High-grade BCG Unresponsive Non-muscle Invasive Bladder Cancer (PHASE3)
- Intravesical BCG vs GEMDOCE in NMIBC (PHASE3)
- Intravesical Gem/Doce in Patients With NMIBC (PHASE2)
- Intravesical Chemotherapy in Combination With Systemic Pembrolizumab in NMIBC Unresponsive or Exposed to BCG Therapy (PHASE2)
- Intravesical Gemcitabine and Docetaxel for BCG naïve Non-muscle Invasive Bladder Cancer (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Intravesical Gemcitabine and Docetaxel CI brief — competitive landscape report
- Intravesical Gemcitabine and Docetaxel updates RSS · CI watch RSS
- Michael A. O'Donnell portfolio CI
Frequently asked questions about Intravesical Gemcitabine and Docetaxel
What is Intravesical Gemcitabine and Docetaxel?
Intravesical Gemcitabine and Docetaxel is a Small molecule drug developed by Michael A. O'Donnell.
Who makes Intravesical Gemcitabine and Docetaxel?
Intravesical Gemcitabine and Docetaxel is developed by Michael A. O'Donnell (see full Michael A. O'Donnell pipeline at /company/michael-a-o-donnell).
What development phase is Intravesical Gemcitabine and Docetaxel in?
Intravesical Gemcitabine and Docetaxel is in Phase 2.